Uncategorized
Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease. The study is a multi-center, randomized, double-masked, and placebo-controlled phase 3 clinic